LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Vintura joins EuropaBio: Creating meaningful impact for patients and health systems

13/02/2025

PRESS RELEASE

Brussels, 13 February 2025 - EuropaBio is excited to announce that Vintura has joined the association.

Founded in 2000, Vintura is a strategy consultancy dedicated to life sciences and healthcare. Its mission is to create meaningful impact for patients and health systems. With offices in the Netherlands, the UK, Germany and France, Vintura is a leading worldwide provider of holistic solutions for pharma and biotech, as well as care providers, payers and policy makers.

In joining EuropaBio, Vintura will further strengthen their network in the European biopharma industry whilst contributing to the dialogue around building a competitive and patient-centred healthcare ecosystem.

Dr. Claire Skentelbery, Director General of EuropaBio said “Vintura brings a valuable voice for the role of patients and innovation within robust health systems. We have to bring all stakeholders together for Europe’s healthy future and we are delighted that Vintura helps build advocacy strength.”

Casper Paardekooper, Partner & Board Member at Vintura had this to say "We are excited to join EuropaBio, as we have very aligned missions. With a large number of EU policy changes happening (EU HTA, GPL, Biotech Act), it is critical to strategically prepare and collaborate.”

For more information on Vintura, please visit vintura.com

Vintura joins EuropaBio: Creating meaningful impact for patients and health systems


Download
Share
Adrian Lincoln
Adrian Lincoln

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

EuropaBio AGM 2025: Association Chair, Executive Committee and Board announced


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.